ArticleAnnals of hematology2022

Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.

Juraj Sokol et al.PubMed ↗Publisher ↗

No numbers read from the abstract.